Special Issue "Anthrax Treatment"

A special issue of Pathogens (ISSN 2076-0817).

Deadline for manuscript submissions: 31 August 2020.

Special Issue Editor

Asst. Prof. Dr. William S. Lawrence
Website
Guest Editor
Department of Microbiology and Immunology, University of Texas Medical Branch
Interests: anthrax; anthrax pathogenesis; anthrax pathophysiology; vaccines; therapeutics; toxins; inhalation models of infection; immunity

Special Issue Information

Dear Colleagues,

Anthrax infection, caused by the bacteria Bacillus anthracis, is a zoonotic disease that retains the attention of the scientific community due to its potential association with bioterrorism. The bacteria produces two toxins, lethal toxin and edema toxin, which promote disease progression and have a myriad of pathological/physiological effects on the host. In the case of inhalation anthrax, the mortality rate is 80% or higher if no treatment is given or if treatment is delayed.  Therapeutic treatment of anthrax infection includes the use of various antibiotics, which, if administered soon enough, are very effective; however, due to the possible emergence of antibiotic-resistant bacterial strains, there is a critical need for new antibiotics and antitoxins.  Attempts are being made to address this need through drug development and drug repurposing.  Preventative treatment of anthrax infection is currently achieved by vaccination with the FDA-approved AVA vaccine, but the requirement for multiple injections and annual boosters makes this vaccine less than ideal.  A better vaccine would require fewer injections and would convey long-lasting immunity. For this Special Issue of Pathogens, we invite you to submit research articles, review articles, and short notes, as well as communications related to anthrax treatment, including the development of new drugs, drug repurposing, vaccine development, and immunity.  We look forward to your contribution.

Asst. Prof. Dr. William S. Lawrence
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anthrax
  • Bacillus anthracis
  • vaccine
  • toxins
  • therapeutic
  • immunity
  • drug development

Published Papers

This special issue is now open for submission.
Back to TopTop